1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in pat

Efficacy of quetiapine in treatment of anxiety disorders

  1. aemetha
    Study Author(s):
    Stein, D. J., Bandelow, B., Merideth, C., Olausson, B., Szamosi, J., & Eriksson, H
    Journal Name:
    Human Psychopharmacology: Clinical and Experimental
    Publication Date:
    2011
    Objective Prospectively planned pooled analysis evaluating efficacy and tolerability of acute quetiapine XR monotherapy in generalised
    anxiety disorder.
    Methods Data from three 10-week, randomised, double-blind, placebo-controlled studies of similar design were analysed.
    Results At Week 8, Hamilton Anxiety Rating Scale (HAM-A) total score significantly improved with quetiapine XR: least squares means
    change 13.31, p<0.001 (50 mg/day, n = 452), 14.39, p<0.001 (150 mg/day, n = 673) and 12.50, p<0.05 (300 mg/day, n = 444) versus
    11.30 placebo; significant (p<0.001, n = 665) improvements versus placebo were observed with each dose at Week 1. Significant
    improvements versus placebo at Week 8 are as follows: HAM-A psychic symptom subscale, Montgomery-Åsberg Depression Rating Scale
    total, Pittsburgh Sleep Quality Index global scores for all quetiapine XR doses; HAM-A response and remission rates, HAM-A somatic
    symptom subscale score, Clinical Global Impression-Severity of Illness total score, % patients with Clinical Global Impression-Improvement
    score ≤2 with quetiapine XR 50 and 150 mg/day; and Quality of Life Enjoyment and Satisfaction Questionnaire short form % maximum total
    score with quetiapine XR 150 mg/day. In the quetiapine XR 50, 150 and 300 mg/day and placebo groups, 13.2%, 16.5%, 24.0% and 5.4% of
    patients discontinued because of an adverse event, and 1.9%, 1.4%, 3.7% and 1.8% of patients experienced clinically significant changes in
    glucose. The most common adverse events with quetiapine XR included dry mouth, somnolence, sedation and constipation.
    Conclusion Quetiapine XR monotherapy reduced the symptoms of generalised anxiety disorder, with improvement from Week 1. Adverse
    events were consistent with the known tolerability profile of quetiapine. Copyright © 2011 John Wiley & Sons, Ltd.